Abstract
Although improved survival in children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL) has been demonstrated in trials, the outcome appears to be inferior in low- and middle-income countries (LMIC). Methods A file review of children aged ≤ 15 years diagnosed with Ph-ALL from 2010 to 2019 was performed. Minimal residual disease (MRD) was assessed by flow-cytometry. Real-time polymerase chain reaction (qRT-PCR) was used to quantify the BCR::ABL1 transcripts during treatment. Results The mean age of the 20 patients in the study was 91 months. Of 19 patients in whom the BCR::ABL1 transcript was confirmed, 10(50%) had P210, 7(35%) had P190, and two showed dual expression. The mean dose of imatinib that was administered was 294 ± 41 mg/m2/day. qRT-PCR for BCR::ABL1 was < 0.01% in all patients who were in remission or had a late relapse and was ≥ 0.01% in patients who had an early relapse. Two patients underwent HSCT. The 3-year event-free survival (EFS) was 35.0 ± 10.7%. Patients with a good prednisolone response (GPR) and a negative end-of-induction MRD demonstrated a superior EFS to those who lacked either or both (80.0 ± 17.9% vs. 16.7 ± 15.2%, P = 0.034). Conclusion The 3-year EFS of 20 children with Ph-ALL treated with chemotherapy and TKI was < 50%. An unusually high proportion of patients with p210 transcript expression; sub-optimal TKI dosing and lesser intensity of chemotherapy, due to the concern of high treatment-related mortality in LMIC are possible reasons for the poor outcome. Conventional treatment response parameters such as GPR and MRD predict outcomes in Ph-ALL. qRT-PCR for BCR::ABL1 may have a role in predicting early relapse.
Similar content being viewed by others
Data Availability
The data supporting this study’s findings are available from the corresponding author [ST], upon reasonable request.
References
Leoni V, Biondi A (2015) Tyrosine kinase inhibitors in BCR-ABL positive acute lymphoblastic leukemia. Haematologica 100:295–299
Schultz KR, Bowman WP, Aledo A et al (2009) Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children’s oncology group study. J Clin Oncol 27:5175–5181
Bhojwani D, Yang JJ, Pui CH (2015) Biology of childhood acute lymphoblastic leukemia. Pediatr Clin North Am 62:47–60
Slayton WB, Schultz KR, Silverman LB, Hunger SP (2020) How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults. Pediatr Blood Cancer 67:e28543
Kulkarni KP, Marwaha RK (2012) Outcome of T cell and other high risk subtypes of acute lymphoblastic leukemia in India: an under-reported entity. Pediatr Hematol Oncol 29:565–567
Biondi A, Schrappe M, De Lorenzo P et al (2012) Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 13:936–945
Athale U, Hijiya N, Patterson BC et al (2019) Management of chronic myeloid leukemia in children and adolescents: recommendations from the children’s Oncology Group CML Working Group. Pediatr Blood Cancer 66:e27827
Cherian T, John R, Joseph LL et al (2021) Complete peripheral blast clearance is superior to the conventional cut-off of 1000/µL in predicting relapse in pediatric pre-B acute lymphoblastic leukemia. Indian J Hematol Blood Transfus 37:366–371
Arunachalam AK, Janet NB, Korula A et al (2020) Prognostic value of MRD monitoring based on BCR-ABL1 copy numbers in Philadelphia chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma 61:3468–3475
Batra S, Ross AJ (2021) Pediatric mixed-phenotype acute leukemia: what’s New? Cancers 13:4658
Thomas D (2012) Childhood Philadelphia-chromosome-positive B-lymphoblastic leukaemia. Lancet Oncol 13:860–862
Alshomar A, El Fakih R (2022) Philadelphia chromosome-positive T-cell acute lymphoblastic leukemia: a case report and review of the literature. Hematol Oncol Stem Cell Ther 15:59–62
Yin MM, Wu RC, Gao J et al (2022) Cytogenetic characteristics of childhood acute lymphoblastic leukemia: a study of 1541 chinese patients newly diagnosed between 2001 and 2014. Curr Med Sci 42:201–209
Bahoush G, Nojoomi M (2019) Frequency of cytogenetic findings and its Effect on the Outcome of Pediatric Acute Lymphoblastic Leukemia. Med Arch 73:311–315
Agarwal M, Seth R, Lall M (2020) Study of Cytogenetic alterations and Association with prognostic factors in Indian Children with B-Lineage Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk 20:e346–e351
Biondi A, Cario G, De Lorenzo P et al (2019) Long-term follow up of pediatric Philadelphia positive acute lymphoblastic leukemia treated with the EsPhALL2004 study: high white blood cell count at diagnosis is the strongest prognostic factor. Haematologica 104:e13–e16
Shen S, Chen X, Cai J et al (2020) Effect of Dasatinib vs Imatinib in the treatment of Pediatric Philadelphia chromosome–positive Acute Lymphoblastic Leukemia. JAMA Oncol 6:358–366
Yamashita S, Umemura T, Sadamura S et al (1996) Acute leukemias expressing p210-and p 190-type bcr/abl mRNAs: report of two cases and review of the literature. Acta Haematol 96:99–104
Winter SS, Greene JM, McConnell TS, Willman CL (1999) Pre-B acute lymphoblastic leukemia with b3a2 (p210) and e1a2 (p190) BCR-ABL fusion transcripts relapsing as chronic myelogenous leukemia with a less differentiated b3a2 (p210) clone. Leukemia 13:2007–2011
Schultz KR, Carroll A, Heerema NA et al (2014) Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: children’s Oncology Group study AALL0031. Leukemia 28:1467–1471
Cazzaniga G, De Lorenzo P, Alten J et al (2018) Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the european intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Haematologica 103:107–115
Trehan A, Bansal D, Varma N, Vora A (2017) Improving outcome of acute lymphoblastic leukemia with a simplified protocol: report from a tertiary care center in north India. Pediatr Blood Cancer 64. https://doi.org/10.1002/pbc.26281
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
None of the authors have anything to disclose.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic Supplementary Material
Below is the link to the electronic supplementary material.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Antonisamy, N., Boddu, D., John, R. et al. The Outcome of Pediatric Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Experience from a Referral Center in South India. Indian J Hematol Blood Transfus 40, 61–67 (2024). https://doi.org/10.1007/s12288-023-01684-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12288-023-01684-9